The identification of altered biomarkers such as osteocalcin, PINP, ALP, OPN, COMP, HA, IGF-1, myostatin, follistatin, and creatine kinase can provide a foundation for developing minimally invasive diagnostic tools to detect early bone, cartilage, and muscle involvement in COVID-19 patients. This evidence concerns the gene COMP and COVID-19.